In May 2024, the MammoScreen project held its first stakeholder workshop in Lisbon, bringing together healthcare professionals, researchers, policymakers and patient representatives to discuss the future of breast cancer screening and the potential role of novel devices.
As the project enters its final phase, a second stakeholder workshop will take place during the upcoming in person-event on 23-24 June 2026 in Brussels. This step marks an important milestone in the project’s journey, providing a timely opportunity to reflect on progress, share emerging results and discuss the next steps towards real-world implementation of technologies, such as MammoWave®. With the large-scale clinical study nearing completion and the ongoing health technology assessment, the project is probing the critical phase of translation – how to bring this innovation into healthcare systems.
The upcoming workshop will gather expert stakeholders from across Europe to ensure that the project’s outcomes are not only scientifically sound, but also aligned with real-world needs, regulatory framework, and patient expectations. Building on the foundations laid during the first stakeholder meeting in 2024, where discussions focused on identifying challenges and shaping the project’s direction, this event will concentrate on validating results, refining implementation strategies and addressing remaining barriers to adoption.
Key topics will include the clinical outcomes, MammoWave®’potential role alongside existing screening methods, cost-effectiveness and practical considerations for integration into national screening programmes. Stakeholders will also explore how to ensure equitable access, improve patient experience and maintain trust in new screening technologies.
As the project approaches its conclusion, this dialogue becomes increasingly important. Successfully introducing a new medical technology requires more than evidence; It demands collaboration, transparency, and alignment between all actors involved in healthcare decision-making.
The Brussels workshop will, therefore, play a crucial role in shaping the legacy of the MammoScreen Project, helping to ensure that its results can translate into meaningful impact, contributing to a more inclusive, patient-friendly and effective breast cancer screening across Europe.